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Abstract
Background
Vitamin D modulates the inflammatory and immune response to tuberculosis (TB) and also
mediates the induction of the antimicrobial peptide cathelicidin. Deficiency of 25-hydroxyvi-
tamin D and single nucleotide polymorphisms (SNPs) in the vitamin D receptor (VDR) gene
may increase the risk of TB disease and decrease culture conversion rates in drug suscepti-
ble TB. Whether these VDR SNPs are found in African populations or impact multidrug-
resistant (MDR) TB treatment has not been established. We aimed to determine if SNPs in
the VDR gene were associated with sputum culture conversion among a cohort of MDR TB
patients in South Africa.
Methods
We conducted a prospective cohort study of adult MDR TB patients receiving second-line
TB treatment in KwaZulu-Natal province. Subjects had monthly sputum cultures performed.
In a subset of participants, whole blood samples were obtained for genomic analyses.
Genomic DNA was extracted and genotyped with Affymetrix Axiom Pan-African Array. Cox
proportional models were used to determine the association between VDR SNPs and rate
of culture conversion.
Results
Genomic analyses were performed on 91 MDR TB subjects enrolled in the sub-study; 60%
were female and median age was 35 years (interquartile range [IQR] 29–42). Smoking was
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reported by 21% of subjects and most subjects had HIV (80%), were smear negative (57%),
and had cavitary disease (55%). Overall, 87 (96%) subjects initially converted cultures to
negative, with median time to culture conversion of 57 days (IQR 17–114). Of 121 VDR
SNPs examined, 10 were significantly associated (p<0.01) with rate of sputum conversion
in multivariable analyses. Each additional risk allele on SNP rs74085240 delayed culture
conversion significantly (adjusted hazard ratio 0.30, 95% confidence interval 0.14–0.67).
Conclusions
Polymorphisms in the VDR gene were associated with rate of sputum culture conversion in
MDR TB patients in this high HIV prevalence setting in South Africa.
Introduction
In 2015 there were an estimated 480,000 cases of multidrug-resistant (MDR) tuberculosis (TB)
worldwide [1]. MDR TB (resistance to at least isoniazid and rifampin) treatment is less effec-
tive, more toxic and costly compared to drug susceptible TB [2]. Importantly MDR TB is asso-
ciated with poor TB treatment outcomes and increased risk of death [3, 4], in 2014 there were
an estimated 190,000 deaths from MDR TB [5]. Despite global efforts, MDR TB remains diffi-
cult to diagnose and treat, and few new therapeutic options are available [6].
Given the paucity of new drugs available for the treatment of MDR TB there has been sub-
stantial clinical interest in adjunctive use of 25-hydroxyvitamin D (vitamin D) to improve TB
—including MDR TB—treatment outcomes [7]. Vitamin D has anti-inflammatory and anti-
bacterial properties that could theoretically improve clinical TB outcomes. The active metabo-
lite of vitamin D, calcitriol, mediates innate immune responses via the induction of the antimi-
crobial peptide cathelicidin and reactive oxygen intermediates. Vitamin D also promotes
macrophage-mediated killing of Mycobacterium tuberculosis and modulates both anti-inflam-
matory and pro-inflammatory T-helper responses to TB [8, 9]. Low exposure to solar ultravio-
let light, inadequate intake of vitamin D and its precursors, or particular genotypes of the
vitamin D receptor (VDR) may lead to vitamin D deficiency which, in turn, could inhibit
reduction of bacillary burden, inhibit culture conversion, and impair the effectiveness of TB
treatment. Despite the hypothesized plausibility that vitamin D supplementation may improve
TB treatment outcomes and the pervasiveness of vitamin D deficiency, clinical trials to date
among patients with drug susceptible TB have not demonstrated efficacy in improving rate of
sputum culture conversion [10–12]. However, evidence suggests that the effects of vitamin D
may vary based on vitamin D receptor (VDR) genotypes, implying that supplementation may
only be of clinical benefit in subpopulations with a particular VDR genotype [13].
In certain ethnic populations, single nucleotide polymorphisms (SNPs) in the vitamin D
receptor (VDR) gene may increase the risk of TB disease [14]. Three previous studies have
reported an association between VDR gene polymorphisms and smear or culture conversion
time in patients with pulmonary TB [15–17]. However, the extent to which VDR SNPs are
found in African populations or impact MDR TB treatment is limited. South Africa has a high
burden of drug-resistant TB, with an estimated 13,000 MDR TB cases in 2014 and 2% MDR
TB prevalence rate among all new TB cases [5]. In this context, we aimed to determine if SNPs
in the VDR gene were associated with time to sputum culture conversion among a cohort of
MDR TB patients in South Africa.
Vitamin D receptor gene polymorphisms and MDR TB
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Methods
Parent study
The SHOUT study was a prospective observational cohort study among patients receiving sec-
ond-line TB treatment for MDR TB from three sites in KwaZulu-Natal province, South Africa
between 2011 and 2015. KwaZulu-Natal is the South African province that has been most
severely affected by TB (incidence: 1076 cases per 100,000 population) and HIV (prevalence:
17%) [18, 19]. Patients 18 years or older were eligible to participate if they had a sputum cul-
ture positive for M. tuberculosis with phenotypic resistance to both isoniazid and rifampin.
Patients with unknown HIV status at the time of enrollment were offered an HIV test. Patients
were excluded if they had previous MDR TB treatment, resistance to either fluoroquinolones
or injectable TB medications, renal or hepatic dysfunction, or were pregnant. Subjects were
treated with the standardized South African MDR TB regimen of kanamycin, moxifloxacin,
ethionamide, terizidone, ethambutol, and pyrazinamide. Kanamycin was typically given for a
minimum of 6 months, or 4 months after culture-conversion, and oral medications were con-
tinued without kanamycin for an additional 12–18 months after culture-conversion. All HIV
co-infected participants were initiated on ART within 2 months of MDR TB treatment initia-
tion, regardless of CD4 count, if they were not already receiving ART. Standard ART regimens
consisted of efavirenz, and stavudine and lamivudine prior to 2013, or tenofovir and emtricita-
bine afterwards. Study participants were seen monthly for follow-up for the duration of MDR
TB treatment, which is typically 21–24 months.
Study population, measures and definitions
The current study was conducted among a subset of patients from the parent SHOUT MDR
TB study who consented to have whole blood samples collected for genomic analyses. Sub-
study patients had the same inclusion/exclusion criteria as the parent study and were enrolled
beginning in April 2013 until the target (n = 100) was reached.
Measures and definitions
The primary outcome of interest for the study was time to initial sputum culture conversion.
Sputum cultures were performed monthly during MDR TB treatment. Mycobacterial cultures
and drug-susceptibility testing (DST) were performed as previously described [4]. Time to
sputum culture conversion was defined by the number of days between MDR TB treatment
initiation and the first of two negative sputum cultures [20]. Patients who converted sputum
cultures to negative before the start of MDR TB treatment were defined as having a 1 day con-
version time. A secondary outcome of interest was poor tuberculosis treatment outcome and
was defined as a patient who died, interrupted treatment, or had treatment failure.
The primary exposures of interest were VDR gene polymorphisms. Participant samples
were genotyped using the Affymetrix1 Axiom Pan-African Array according to the manufac-
turer’s instructions [21]. Quality checks were performed to ensure the overall SNP call rate was
95% and that there was no sex mismatch between genotypic and phenotypic measurement.
SNPs were excluded if they had an unknown chromosomal location, a call rate less than 95%, a
Hardy-Weinberg Equilibrium (HWE) p-value less than 0.0001 or a minor allele frequency
(MAF) less than 0.05. After quality control filters, 1,494,763 SNPs were available for genetic
analysis. South African samples were pooled with HapMap EUR, YRI and ASW populations
to identify population structure relative to European and West African ancestry [22]. Top
principal components (PCs) were calculated using independent SNPs after pruning by pair-
wise linkage disequilibrium R2 larger than 0.1 within windows of 50 SNPs. Using base pair
Vitamin D receptor gene polymorphisms and MDR TB
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location of human genome build 37, there were 121 SNPs annotated to the VDR gene and
passed quality control filters.
Smoking status and alcohol use were self-reported by study patients. Both smoking status
and alcohol use were categorized dichotomously as current use (yes/no).
Statistical analyses
We examined 121 VDR SNPs to assess their association with rate of sputum culture conver-
sion among patients with MDR TB. Each SNP was coded using the additive genetic effect. Cox
proportional models were used to determine the association between VDR SNPs (additive
effect) and the hazard rate of initial sputum culture conversion. Patients who had a positive
culture at time of MDR TB diagnosis but converted sputum cultures to negative before the
start of MDR TB treatment were censored at day 1. Patients who died or failed treatment
before an initial sputum culture conversion were censored. All models were adjusted for age,
sex, smoking status, alcohol, AFB smear status, HIV status, and cavitary disease. For the sec-
ondary outcome of TB treatment result, we used logistic regression to estimate the odds of
poor TB treatment outcome among a subset of SNPs associated with reduced rate of culture
conversion. Patients who withdrew from the study before treatment completion were excluded
from the secondary outcome analysis.
Ethics
The study protocol was approved by the institutional review boards at the University of Kwa-
Zulu-Natal, Albert Einstein College of Medicine, and Emory University, and by the KwaZulu-
Natal Department of Health and CDC’s National Center for HIV, Hepatitis, STDs and Tuber-
culosis. All participants signed written informed consent.
Results
Participant characteristics
From 2011–2013, the parent cohort study screened 365 patients and enrolled 206. Among
patients enrolled in the parent study, 103 provided samples for the present sub-study, 7 were
not processed due to DNA extraction errors, and 5 patients were late excluded from the parent
study due to second line drug resistance. The 91 remaining participants were included in the
current sub-study for genomic analyses and of these, 55 (60%) were female and the median
age was 35 years (interquartile range [IQR] 29–42) (Table 1). Most patients were HIV co-
infected (n = 73, 80%), had undetectable viral load (n = 23/42, 55%) and the median baseline
CD4 count of 199 cells/mm3 (IQR 143–289). Thirty-nine (43%) patients were AFB smear posi-
tive, 50 (55%) had cavitary disease, and 74 (81%) had previously been treated for TB. Smoking
was reported by 21% of patients.
Genome-wide association principal components
All samples passed standard genome-wide association study (GWAS) quality control filters
with the lowest individual level SNP call rate of 98.2%. Using top two PCs from GWAS data
(Fig 1), we observed the separation of South Africans from populations with known African
ancestry (YRI and ASW), and European ancestry (EUR). PC1 clustered European versus Afri-
can ancestry, while PC2 further distinguished West Africans and South Africans. Within
South African samples in this study, no outlier (3SD) was observed using top 10 PCs, indicat-
ing a genetically homogeneous population.
Vitamin D receptor gene polymorphisms and MDR TB
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Sputum culture conversion
Overall, 87 (96%) subjects converted sputum cultures to negative. Of the 87 who converted
sputum cultures to negative, 24% (21/87) were positive at the time of MDR TB diagnosis but
converted to negative before the time of MDR TB treatment start. The median time to culture
conversion was 57 days (IQR 17–114); among patients who were not culture negative at time
of treatment initiation the median time to conversion was 82 days (IQR 53–143). Among
patients who converted, 50 (55.0%) were culture negative by two months of second-line treat-
ment (Table 1). Compared to females, males were significantly more likely to be sputum cul-
ture positive at two months (36.4% [20/55] vs. 58.3% [21/36], p = 0.04).
Of 121 VDR SNPs examined, 10 were significantly associated (p<0.05) with hazard rate of
sputum culture conversion in multivariable analyses (Table 2). The estimated slower conver-
sion rate (adjusted hazard ratio of sputum culture conversion <1.0) ranged from 0.30 (95% CI
0.14–0.67) for rs74085240 to 0.64 (95%CI 0.42–0.98) for rs11168287. For example, each addi-
tional risk allele on SNP rs74085240 delayed the rate of culture conversion by 70% (aHR 0.55,
95% CI 0.36–0.85). Two VDR SNPs (rs11168327 and rs11574143) were associated with signifi-
cantly improved rate (adjusted hazard ratio >1.0) of culture conversion (Table 2). The VDR
SNPs not significantly associated with hazard rate of sputum culture conversion are listed in
S1 Table.
Overall, 19% (17/88) of patients had a poor TB treatment outcome and 3 additional patients
withdrew treatment. We did not detect any genotypes associated with a significant increased
odds of poor TB treatment outcome (Table 3).
Discussion
We examined 121 SNPs in the VDR gene region and found a subset to be associated with rate
of sputum culture conversion among patients with MDR TB in South Africa. Specifically, we
Table 1. Baseline participant characteristics and 2-month sputum culture status.
Characteristic Total
N = 91
N (%)
Sputum culture negative at 2-months
N = 50 (55.0)
N (%)
Sputum culture positive at 2-months
N = 41 (45.1)
N (%)
P valueA
Male 36 (39.6) 15 (30.0) 21 (51.2) 0.04
Median age, years (IQR) 35 (29–42) 35 (27–41) 38 (32–42) 0.12
Current smokerB 19 (20.9) 7 (14.0) 12 (29.3) 0.07
AlcoholB 28 (30.7) 14 (28.0) 14 (34.2) 0.53
Baseline AFB positive 39 (42.9) 18 (36.0) 21 (51.2) 0.14
Baseline cavity 50 (55.0) 26 (52.0) 24 (58.5) 0.53
Median baseline BMI (IQR) N = 82 21.6 (18.5–24.6) 21.8 (19.4–24.4) 21.3 (16.8–24.9) 0.42
Previous TB treatment 74 (81.3) 40 (80.0) 34 (82.9) 0.72
HIV seropositive 73 (80.2) 40 (80.0) 33 (80.5) 0.95
Median baseline CD4 (IQR) N = 46C
199 (143–289)
185 (125–266) 221 (143–309) 0.61
On ARV at baselineC N = 57 44 (75.7) 24 (75.0) 20 (76.9) 0.66
Median baseline viral load (IQR) N = 42C 83 (39–13000) 65 (39–75278) 100 (39–3200) 0.94
Undetectable viral load N = 42C 23 (54.8) 13 (56.5) 10 (52.6) 0.80
Table 1 abbreviations: IQR-interquartile range; AFB-acid fast bacilli; ARV-antiretroviral
A. 2-side chi-square p-value, except for age (2-sided Wilcoxon rank sum)
B. Self-reported
C. Among HIV positive only
https://doi.org/10.1371/journal.pone.0180916.t001
Vitamin D receptor gene polymorphisms and MDR TB
PLOS ONE | https://doi.org/10.1371/journal.pone.0180916 July 10, 2017 5 / 11
Fig 1. Principal component analysis of study participants compared to HapMap ethnic groups.
https://doi.org/10.1371/journal.pone.0180916.g001
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identified 9 VDR SNPs that were associated with an estimated 50% to 25% reduced (delayed
conversion) rate of sputum culture conversion among patients receiving second-line TB ther-
apy. Our findings provide new data about the relationship between VDR polymorphisms and
sputum culture conversion among patients with MDR TB in South Africa.
Our findings in patients with MDR TB are consistent with three previous studies that
reported significantly lower rates of sputum culture conversion among patients with drug sus-
ceptible pulmonary TB who had specific VDR polymorphisms [10, 15, 17]. First, an observa-
tional longitudinal study among 78 Peruvian patients with confirmed pulmonary TB reported
that patients with the TT TaqI genotype (previous nomenclature now typically replaced by
endonuclease digestion pattern) had significantly longer time to sputum culture conversion
(median 46 days for TT genotype vs. 16 days for Tt genotype) [15]. Second, in 2011 Martineau
et al conducted a randomized control trial in London, testing the efficacy of 2.5mg vitamin D3
supplementation to reduce culture conversion time in smear positive TB patients [10]. The
trial reported no overall effect of supplementation on culture conversion rates, but the authors
did report an interaction between vitamin D3 supplementation and culture conversion with
TaqI genotype. Specifically, supplementation was beneficial among patients with tt genotype
(HR 8.09, 95%CI 1.36–48.01). Unlike the studies from Peru and London, we did not observe
an association between rs731236 (TaqI genotype defined by endonuclease digestion pattern)
and rate of sputum culture conversion. Third, an observational longitudinal study of HIV-neg-
ative patients with pulmonary TB from the Western Cape of South Africa reported that a sig-
nificantly lower proportion of patients with ApaI aa genotype had converted cultures by
month 2 of TB treatment compared to patients with ApaI Aa genotype (26% vs. 51%, p = 0.03)
[17]. All three studies are consistent with our findings that VDR polymorphisms are associated
with rate of culture conversion. Unlike the previous studies, our study identified SNPs signifi-
cantly associated with rate of culture conversion in patients with MDR TB.
To our knowledge, only one previous study examined the association between VDR geno-
types and time to culture conversion in patients with MDR TB. In 2012 Rathored et al. fol-
lowed 236 HIV-negative patients with MDR TB during DOTS-Plus treatment in India and
reported no significant differences in bivariate analyses between the three VDR genotypes
Table 2. Hazard of sputum culture conversion by vitamin D receptor gene single nucleotide polymorphism.
SNP Model
N
DaysA (IQR) HR 95% CI P valueB Adjusted
N
aHRC 95% CI P valueB
rs74085240 88 57 (17–113) 0.54 0.28–1.07 0.077 88 0.30 0.14–0.67 0.003
rs1015390 88 55 (19–90) 0.67 0.46–0.99 0.045 88 0.54 0.35–0.82 0.004
rs4073729 91 56 (27–114) 0.72 0.50–1.05 0.085 91 0.56 0.37–0.85 0.006
rs11168268 91 55 (1–111) 0.63 0.42–0.94 0.024 91 0.55 0.36–0.85 0.008
rs2525044 91 55 (1–111) 0.57 0.33–0.97 0.038 91 0.46 0.24–0.86 0.015
rs11168287 91 57 (19–122) 0.76 0.52–1.09 0.139 91 0.64 0.42–0.98 0.040
rs2238139 91 55 (1–108) 0.66 0.43–1.01 0.054 91 0.60 0.37–0.98 0.042
rs11574138 91 57 (1–113) 0.78 0.39–1.57 0.486 91 0.43 0.19–1 0.049
rs11168327 91 84 (41–131) 1.30 0.90–1.88 0.155 91 1.81 1.16–2.84 0.009
rs11574143 91 72 (26–156) 1.73 1.02–2.93 0.041 91 2.05 1.16–3.63 0.014
Table 2 abbreviations: IQR-interquartile range; SNP-single nucleotide polymorphism; CI-confidence interval; rs-reference SNP
A. Median days to sputum culture conversion among SNPs carrying 0 effect alleles
B. Wald test p-value, SNPs are listed in ascending order based on p-value
C. Hazard ratios estimated from Cox Proportional regression models adjusted for age, sex, smoking status, alcohol, AFB smear status, HIV status, and
cavitary disease; SNPs modelled additively, hazard ratio indicates per additional risk allele on each SNP.
https://doi.org/10.1371/journal.pone.0180916.t002
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examined (BsmI, TaqI, FokI) and time to culture conversion [16]. However, in our study we
examined 121 specific SNPs on the VDR gene region and adjusted for important confounding
factors (i.e., smoking status); Rathored et al. did not adjust for confounding which may par-
tially explain why we reported significant differences in rates of culture conversion and the
previous study did not. Similar to the study in India, we did not observe a significant associa-
tion between BsmI (rs1544410) or TaqI (rs731236) genotypes and time to culture conversion.
Several hypothesized biologic mechanisms may explain why polymorphisms in the VDR
gene are associated with rate of sputum culture conversion in patients with MDR TB.
Although vitamin D supplementation has not been demonstrated to be efficacious in improv-
ing culture conversion time in drug-susceptible TB treatment [10–12], vitamin D likely has a
role in TB treatment-induced modulation of circulating immunologic signals. Circulating
immune signals are affected by TB treatment alone, for example interleukin (IL)-10, cathelici-
din LL-37, and neutrophil gelatinase-associated lipocalin (NGAL) are suppressed by medica-
tions administered during the intensive phase TB treatment. Moreover, a randomized trial
Table 3. Poor tuberculosis treatment outcome by vitamin D receptor gene single nucleotide polymorphism, N = 88.
SNP Total
N = 88
Poor OutcomeA
N = 17 (19.3)
N (%)
Cured/Completed
N = 71 (80.7)
N (%)
Odds ratio
(95% CI)
Adjusted odds ratioB
(95% CI)
rs74085240*
CC 2 1 (50.0) 1 (50.0) 4.07 (0.24–68.83) 3.91 (0.23–67.00)
CA 8 1 (12.5) 7 (87.5) 0.58 (0.07–5.09) 0.59 (0.07–5.13)
AA 76 15 (19.7) 61 (80.3) 1.00 1.00
NA 2 0 2 (100)
rs11574138*
CC 1 0 1 (100) NA NA
CT 8 3 (37.5) 5 (62.5) 2.79 (0.60–13.04) 2.73 (0.57–13.15)
TT 79 14 (17.7) 65 (82.3) 1.00 1.00
rs11168268*
GG 9 3 (33.3) 6 (66.7) 2.50 (0.50–12.46) 2.45 (0.49–12.32)
GA 37 7 (18.9) 30 (81.2) 1.17 (0.37–3.71) 1.16 (0.36–3.69)
AA 42 7 (16.7) 35 (83.3) 1.00 1.00
rs2525044*
AA 2 1 (50.0) 1 (50.0) 5.09 (0.30–87.68) 5.00 (0.29–87.68)
AG 19 5 (26.3) 14 (73.7) 1.82 (0.54–6.09) 1.80 (0.53–6.11)
GG 67 11 (16.4) 56 (83.6) 1.00
rs1015390*
TT 9 2 (22.2) 7 (77.8) 0.86 (0.15–1.53) 0.91 (0.15–5.42)
TC 44 6 (13.6) 38 (86.4) 0.47 (0.15–5.00) 0.43 (0.13–1.43)
CC 32 8 (25.0) 245 (75.0) 1.00 1.00
NA 3 1 (33.3) 2 (66.7)
rs2238139
GG 5 2 (40.0) 3 (60.0) 3.33 (0.49–22.60) 3.32 (0.49–22.52)
GA 23 5 (21.7) 18 (78.3) 1.39 (0.42–4.62) 1.36 (0.41–4.57)
AA 60 10 (16.7) 50 (83.3) 1.00 1.00
Table 3 abbreviations: SNP-single nucleotide polymorphism; rs-reference SNP; CI-confidence interval; NA-snp information not available
A. Poor outcome defined as death or failure.
B. Adjusted for HIV status
https://doi.org/10.1371/journal.pone.0180916.t003
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from London demonstrated that vitamin D supplementation enhanced the immune effects of
TB treatment. In the trial of 126 smear-positive pulmonary TB patients, Coussens et al. re-
ported that patients receiving vitamin D supplementation during first-line treatment had TB
treatment-induced increases in lymphocytes and reduced concentrations of inflammatory
markers [23]. Therefore, it is plausible that effects of second-line TB treatment on the immune
responses may be modified differently by vitamin D compared to first-line TB treatment
immune modulation by vitamin D.
Our study was subject to limitations. First, we did not measure plasma levels of vitamin D
or calcitriol. Therefore, we were unable to verify if vitamin D levels were affected by polymor-
phisms in the VDR SNPs or if the polymorphisms affected culture conversion directly. Second,
we did not measure any immune modulating signals. Vitamin D is hypothesized to affect spu-
tum culture conversion through immune modulation of cytokines (interferon-gamma, IL-2,
IL-12) chemokines (chemokine ligand (CXCL)-9, CXCL-10, matrix metallopeptidase-9) and
antigen stimulated responses (Th1) [23]. Consequently, we were unable to determine if VDR
SNPs influenced the expression of immune modulating signals that may affect rate of culture
conversion. Third, our sample had relatively low power and we were therefore unable to adjust
statistical tests for multiple comparisons. We did not have power to adjust for covariates in the
logistic regression models that were used to estimate the odds of poor MDR TB treatment out-
come by VDR SNPs. Fourth, we did not examine sputum culture reversions to positive. The
analysis only analyzed the association between VDR SNPs and the patients’ first sputum cul-
ture conversion and therefore does not assess the association with sustained conversion.
Despite limitations, our study had several strengths. Foremost, we examined 121 specific
SNPs in the VDR gene region among patients with MDR TB from a genetically distinct popu-
lation. Previous similar studies have focused on VDR polymorphisms at the level of FokI,
ApaI, and TaqI genotypes but did not measure specific SNPs and only one previous study
enrolled patients with TB from South Africa (which included only drug-susceptible patients).
Second, our study only included patients with culture- and DST-confirmed MDR TB and fol-
lowed patients monthly to obtain cultures during second-line TB treatment. Previous studies
examining the association between VDR polymorphisms and response to TB treatment were
primarily among drug susceptible patients, included patients without culture confirmed TB,
largely examined sputum smear conversion at one time point, and few adjusted for key con-
founders [24, 25].
Supporting information
S1 Table. Vitamin D receptor gene single nucleotide polymorphisms not significantly asso-
ciated with initial time to sputum culture conversion.
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